Core Insights - NuGen Medical Devices Inc. is developing a next-generation needle-free injection system aimed at improving drug delivery technology, protected under international patent WO2021206553 [1][2] - The new system integrates a sterile internal insulin cartridge into the needle-free autoinjector, eliminating the need for external connectors and reducing dosing errors and contamination risks [2][6] - The innovation is expected to enhance patient experience for those requiring daily injections, positioning it as a competitor to pen-based injectors [3] Technical Highlights - The internal cartridge integration streamlines the injection process by removing the need for external adaptors and manual filling [6] - A backflow control mechanism is included to ensure precise and safe insulin delivery, addressing unique challenges of jet injection [6] - Improved usability is a focus, simplifying operation for patients and caregivers, which is anticipated to reduce training time and improve compliance [6] Future Milestones - NuGen plans to begin clinical investigations using its currently approved needle-free platform, allowing for parallel development of the new cartridge-based system [6] - The company aims to produce working prototypes within six months to showcase the technology and conduct usability studies [6] - Full tooling investment for scaled manufacturing and commercialization is expected to commence in early 2026 [6] Company Overview - NuGen Medical Devices specializes in next-generation needle-free devices for subcutaneous drug delivery, with its flagship InsuJet™ system approved in 42 countries [5]